证券代码：600196 股票简称：复星医药 编号：临 2025-086 上海复星医药（集团）股份有限公司 关于控股子公司药品纳入突破性治疗药物程序的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、概况 该新药为本集团（即本公司及控股子公司/单位，下同）自主研发的创新型小分 子化学药物，为 MEK1/2 选择性抑制剂，拟主要用于治疗晚期实体瘤、1 型神经纤维 瘤病、树突状细胞和组织细胞肿瘤、低级别脑胶质瘤等。 截至本公告日期（即 2025 年 5 月 12 日），该新药用于治疗成人树突状细胞和 组织细胞肿瘤、2 岁及 2 岁以上儿童 1 型神经纤维瘤病（NF1）相关的丛状神经纤维 瘤（PN）的药品上市注册申请均已获国家药监局受理并被纳入优先审评程序；该新 药用于治疗成人 1 型神经纤维瘤病于中国境内（不包括港澳台地区，下同）处于 III 期临床试验阶段，该新药用于低级别脑胶质瘤、颅外动静脉畸形、儿童朗格汉斯细 胞组织细胞增生症的治疗于中国境内均处于 II 期临床试验阶段，其中，该新药用于 治疗组织细胞肿瘤、无法手术或术 ...

Group 1 - The Shanghai Composite Index opened high and the CSI 300 Pharmaceutical and Biotechnology Index reported 7624.71 points [1] - The CSI 300 Pharmaceutical and Biotechnology Index has increased by 4.46% in the past month, 3.56% in the past three months, and 2.43% year-to-date [1] - The index is designed to reflect the overall performance of different industry companies within the CSI 300 Index, categorized into 11 primary industries, 35 secondary industries, over 90 tertiary industries, and more than 200 quaternary industries [1] Group 2 - The top ten holdings of the CSI 300 Pharmaceutical and Biotechnology Index are: Heng Rui Medicine (25.5%), WuXi AppTec (15.98%), Pian Zai Huang (6.77%), Yunnan Baiyao (5.51%), Kelun Pharmaceutical (4.73%), New Horizon (3.69%), East China Pharmaceutical (3.68%), Shanghai Raist (3.39%), Changchun High-tech (3.33%), and Fosun Pharma (3.23%) [1] - The market segment of the CSI 300 Pharmaceutical and Biotechnology Index shows that the Shanghai Stock Exchange accounts for 63.75% and the Shenzhen Stock Exchange accounts for 36.25% [2] - In terms of industry composition, chemical drugs account for 43.27%, pharmaceutical and biotechnology services for 21.11%, traditional Chinese medicine for 19.35%, and biological drugs for 16.27% [2] Group 3 - The index samples are adjusted every six months, with adjustments implemented on the next trading day after the second Friday of June and December each year [2] - Weight factors are adjusted along with the periodic sample adjustments, which are fixed until the next scheduled adjustment unless a temporary adjustment is required [2] - Special events affecting sample companies may lead to changes in industry classification, and companies that are delisted will be removed from the index [2]

Group 1 - Rumors circulated about Jack Ma's return to Alibaba, but he stated he had not heard of such plans [1] - Alibaba CEO Wu Yongming emphasized the need for the company to return to its entrepreneurial roots and embrace innovation in the face of AI technology [2][3] - Alibaba has reportedly reconnected internal network permissions across various business units, allowing employees to collaborate more effectively [3] Group 2 - Tmall's 618 shopping festival will feature a simplified discount model, offering a 15% reduction on purchases, with additional coupons and discounts available [4] - Douyin has intensified efforts to combat fraudulent tipping practices in live streaming, recovering over 1,000 accounts in the first quarter [5] - Dazhong Dianping has launched a reporting channel for users to report harassment from merchants related to reviews [6] Group 3 - The e-commerce platform Dewu reported a doubling of annual sales for 6,120 brands, with over 500 million users, primarily targeting the post-95 demographic [7] - Xiangdao Travel announced a C-round financing of over 1.3 billion RMB and plans for an IPO in Hong Kong [8] - Shenzhou Car Rental initiated a "dirty must compensate" service quality month to enhance vehicle cleanliness standards [9] Group 4 - Google Pay's regulatory oversight by the U.S. Consumer Financial Protection Bureau has been revoked, reversing a previous decision [10] - Tencent has launched an open-source video generation tool, enhancing capabilities for creating customized videos [11] - Semiconductor manufacturer SMIC indicated potential downward adjustments in inventory targets from smartphone clients due to market conditions [13] Group 5 - TSMC reported a 48.1% year-on-year increase in sales for April, reaching 349.57 billion NTD [14] - Major U.S. tech companies discussed the need for increased infrastructure investment and reduced regulatory barriers for AI at a congressional hearing [15] - Elon Musk's AI startup xAI is in talks for new funding, with a potential valuation increase from $80 billion to $120 billion [17] Group 6 - New Hope reported a sales volume of 1.596 million pigs in April, with a revenue of 2.278 billion RMB [33] - Fangzheng Securities announced a leadership change with the retirement of its president and the appointment of a new president [34] - Fosun Pharma received FDA approval for clinical trials of its self-developed product aimed at treating androgenetic alopecia [35][36] Group 7 - Shimao Group reported a cumulative contract sales amount of approximately 9.07 billion RMB for the first four months of 2025 [37]

Group 1 - Alibaba's CEO Wu Yongming emphasized the need for the company to return to its entrepreneurial roots and adapt to the opportunities and risks presented by the AI technology revolution [3][4] - Alibaba has reportedly opened up internal network permissions, allowing employees from various business units to reconnect after two years, indicating a potential shift towards a more unified corporate culture [4] - Tmall's 618 shopping festival will feature a simplified discount structure, offering a 15% discount for single-item purchases, with additional coupons and price protection measures in place [4] Group 2 - TikTok's live streaming platform has intensified efforts to combat "emotional disguise" scams, recovering over 1,000 accounts in the first quarter for violating guidelines [5] - Dazhong Dianping has launched a reporting channel for users to report inducements for positive reviews and harassment for negative reviews, with significant numbers of complaints received during the recent holiday [6][7] - The e-commerce platform Dewu reported a doubling of annual sales for 6,120 brands, with a user base exceeding 500 million, primarily targeting the post-95 demographic in China [8] Group 3 - Xiangdao Travel has completed over 1.3 billion RMB in Series C financing and announced plans for an IPO in Hong Kong, focusing on personal and corporate travel services [9] - Shenzhou Car Rental has initiated a "dirty must compensate" service quality month, promising triple compensation for users who find vehicles not meeting cleanliness standards [10] - Google Pay has had its regulatory oversight lifted by the U.S. Consumer Financial Protection Bureau, reversing a previous decision made during the Biden administration [11] Group 4 - TSMC reported a 48.1% year-on-year increase in sales for April, reaching 349.57 billion NTD, with a 22.2% month-on-month growth [15] - Semiconductor foundry SMIC indicated that smartphone clients may lower inventory targets for Q3, facing price pressure in the foundry industry [14] - Ford has withdrawn its annual earnings guidance due to potential significant impacts from tariffs on net profits, despite reporting better-than-expected Q1 results [27] Group 5 - Panasonic Holdings announced plans to cut 10,000 jobs by 2029, representing about 4% of its global workforce of approximately 228,000 [32] - New Hope reported a sales volume of 1.596 million pigs in April, with a revenue of 2.278 billion RMB, reflecting a year-on-year decrease in revenue [34] - Shimao Group's contract sales for the first four months of 2025 reached approximately 9.07 billion RMB, with an average sales price of 12,209 RMB per square meter [37]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不 發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損 失承擔任何責任。 （股份代號：02196） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條而作出。 茲載列上海復星醫藥（集團）股份有限公司（「本公司」）在上海證券交易所網站刊登的《關於 控股子公司獲美國FDA藥品臨床試驗批准的公告》，僅供參閱。 承董事會命 上海復星醫藥（集團）股份有限公司 上 海 復 星 醫 藥（ 集 團 ）股 份 有 限 公 司 Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* （於中華人民共和國註冊成立的股份有限公司） 董事長 陳玉卿 中國，上海 2025 年5 月9 日 於本公告日期，本公司之執行董事為陳玉卿先生、關曉暉女士、文德鏞先生及王可心先生；本公司之非執行 董事為陳啟宇先生、徐曉亮先生、潘東輝先生及吳以芳先生；以及本公司之獨立非執行董事為李玲女士、湯 谷良先生、王全弟先生及余梓山先生。 * 僅供識別 证券代码：6 ...

Group 1 - Yitong Century won a bid for a communication engineering construction service project from China Mobile, with a total bid amount of 228 million yuan (including tax) [1] - Zhiyuan New Energy plans to repurchase shares worth between 33 million and 66 million yuan, with a maximum repurchase price of 22.00 yuan per share [1] - GAC Group reported April automobile sales of 116,400 units, a year-on-year decrease of 12.66% [2] - JAC Motors reported April automobile sales of 30,764 units, a year-on-year decrease of 3.55% [3] Group 2 - Fosun Pharma's subsidiary received FDA approval for a clinical trial of a live biotherapeutic product aimed at treating androgenetic alopecia [4] - Liangxin Co. obtained multiple patent certificates, including 2 invention patents and 32 utility model patents [5] - Sainuo Medical's two products received medical device registration certificates in Mexico and Ecuador [5] - Huayu Pharmaceutical's two products received marketing approvals in France and Spain [6] Group 3 - Shengnong Development reported April sales revenue of 1.533 billion yuan, a year-on-year increase of 0.68% [6] - Hasi Lian's potassium chloride and sodium chloride injection passed the consistency evaluation [7] - Shapuaisi received approval for a supplemental application for levofloxacin eye drops [9] - Tianyu Biological reported April sales revenue of 59.32 million yuan from pig sales [10] Group 4 - *ST Weihai was pre-awarded a project worth 108 million yuan [12] - Luoniushan reported April sales revenue of 125 million yuan from pig sales, a year-on-year increase of 12.72% [13] - Minhe Co. reported April sales revenue of 68.30 million yuan from chick sales, a year-on-year increase of 0.51% [14] Group 5 - Double Ring Technology's application for a specific stock issuance was approved by the Shenzhen Stock Exchange [15] - Hualu Hengsheng plans to repurchase shares worth between 200 million and 300 million yuan [16] - Baolong Technology plans to repurchase shares worth between 100 million and 200 million yuan [17] Group 6 - Huasheng Technology's subsidiary plans to sell shares of a company for 200 million yuan [24] - *ST Gengxing's controlling shareholder plans to increase holdings worth between 30 million and 60 million yuan [25] - Ruihuatai's shareholder plans to reduce holdings by up to 1% of the company's shares [26] Group 7 - Foton Motor reported April commercial vehicle sales of 54,816 units, a year-on-year increase of 21.63% [20] - China Merchants Bank plans to invest 15 billion yuan to establish a financial asset investment company [22] - Jinchengxin plans to invest approximately 231 million USD in the Alacran copper-gold-silver mine project [23] Group 8 - Zhongji United's controlling shareholder plans to reduce holdings by up to 2% of the company's shares [30] - Ningbo Huaxiang signed a strategic cooperation agreement to strengthen collaboration in various areas [31] - SMIC reported a net profit of 1.356 billion yuan for Q1 2025, a year-on-year increase of 166.5% [32] Group 9 - FAW Fuwi received a project notification to develop seat products for a luxury brand, with a total sales amount expected to be 1.39 billion yuan [33] - Huakang Clean won a bid for a purification project worth 64.425 million yuan [34] - Lihua Co. reported April sales revenue of 1.125 billion yuan from chicken sales [35]

E-commerce - Suning.com held the 618 e-commerce launch meeting, with offline stores nationwide participating in the promotion starting from May 13, 2023 [1] - The online promotion will also begin on May 13, with multiple promotional events scheduled throughout the 618 period [1] Legal Actions - Italian company Moltiply has filed a lawsuit against Google's parent company Alphabet, seeking €2.97 billion (approximately $3.34 billion) in damages for alleged abuse of market dominance [2] - The lawsuit claims that Google's actions hindered the development of Moltiply's subsidiary, 7Pixel, from 2010 to 2017 [2] Retail and Sales - During the "Young Product New Venue" merchant conference, it was reported that 6,120 brands on the Dewu platform have doubled their annual sales [4] - Dewu has introduced policies to reduce fees for over 30 categories, with a maximum reduction of 16%, and has invested over 1 billion yuan in marketing rebates [4] Automotive Industry - The three major U.S. automakers criticized the trade agreement between President Trump and the UK, which allows UK manufacturers to export 100,000 cars to the U.S. at a 10% tariff rate [5] - This quota is nearly equivalent to the total number of cars exported from the UK last year, raising concerns among U.S. manufacturers about competitive disadvantages [5] Technology and AI - Nvidia has open-sourced several code reasoning models, including 32B, 14B, and 7B parameters, based on Alibaba's Qwen models [6] - Quark, Alibaba's AI application, is set to launch "Deep Search Pro," which aims to assist users in solving complex tasks across various professional fields [10] Aviation - International Airlines Group (IAG) announced the purchase of 53 new long-haul aircraft from Boeing and Airbus, including 32 Boeing 787-10s and 21 Airbus A330-900neos [11] Financial Services - Zhongzheng Asset Management (Jiangsu) Co., Ltd. completed a 30 million yuan angel round of financing to accelerate the development of its intelligent investment advisory platform [8] - The funds will be used for platform development, team expansion, and market outreach [8] Pharmaceuticals - Fosun Pharma's subsidiary received FDA approval to conduct clinical trials for LBP-ShC4, a live biotherapeutic product aimed at treating androgenetic alopecia [9] - The cumulative R&D investment for LBP-ShC4 is approximately 17 million yuan as of April 2025 [9] Regulatory Developments - The People's Bank of China plans to deepen financial reform and enhance the monetary policy framework to support high-quality financial development [12][14] - The China Securities Regulatory Commission aims to strengthen the regulation of capital market activities to maintain a fair market order [13]

关于控股子公司获美国 FDA 药品临床试验批准的公告 证券代码：600196 股票简称：复星医药 编号：临 2025-085 上海复星医药（集团）股份有限公司 截至 2025 年 4 月，本集团现阶段针对 LBP-ShC4 的累计研发投入约为人民币 0.17 亿元（未经审计）。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、概况 上海复星医药（集团）股份有限公司（以下简称"本公司"）控股子公司上海 菌济健康科技有限公司（以下简称"菌济健康"）收到美国 FDA（即美国食品药品 监督管理局）关于同意 LBP-ShC4 开展临床试验的批准。菌济健康拟于条件具备后开 展 LBP-ShC4 的 I 期临床试验。 二、LBP-ShC4 的研究情况 LBP-ShC4 为本集团（即本公司及控股子公司/单位，下同）自主研发的活体生 物治疗产品，拟用于治疗雄激素脱发（AGA）。 截至本公告日期（2025 年 5 月 9 日），于全球范围内尚无用于治疗雄激素脱发 （AGA）的活体生物治疗产品（包括单药或联合治疗方案）获批上市。 三、风险提示 ...

Core Viewpoint - The first "Fosun Cup" AI+ Entrepreneurship and Innovation Competition has been launched, aiming to integrate cutting-edge technology with industry applications, leveraging Fosun's extensive resources and global industry scenarios [1][10]. Group 1: Competition Overview - The competition is supported by Fosun's global investment institution, Fosun Ruijing Capital, which will provide investments ranging from 5 million to 50 million yuan for the top three teams [3][11]. - Winning teams will also gain priority access to over 200 industry application scenarios, including AI applications in finance, healthcare, and intelligent manufacturing [3][11]. - The competition includes cash prizes of 100,000 yuan or equivalent resources for the top teams, along with direct recruitment opportunities for outstanding teams [4][11]. Group 2: Recruitment Tracks - The competition is recruiting AI pioneers across various tracks, including AI+Finance, AI+Healthcare, AI+Marketing, AI for Science (AI4S), and AI+Intelligent Agents [4][11]. - Each track focuses on specific applications of AI, such as financial data processing, drug development, and intelligent marketing solutions [4][11]. Group 3: Competition Schedule - The project recruitment phase runs until June 15, 2025, followed by a selection process to identify over 20 enterprises for the initial round [6][7]. - The initial round will take place from June 15 to June 30, 2025, where 20+ enterprises will compete for a spot in the finals [7]. - The final competition is scheduled for July 2025, where experts and executives will evaluate the projects through presentations [8]. Group 4: Fosun's Strategic Focus - Fosun emphasizes technology innovation as a core strategic pillar, building a global innovation system that integrates independent research, investment incubation, and ecological cooperation [10][11]. - The company has made significant investments in AI and robotics, with a focus on enhancing efficiency in drug development, medical imaging, and precision medicine [10][12]. - Fosun's subsidiaries, including Fosun Pharma and Fosun Wealth Holdings, are actively integrating AI into their operations to improve decision-making, operational efficiency, and market insights [12][14].

Core Insights - The average annual salary of A-share chairpersons shows a significant concentration in the range of 1 million to 2 million yuan, with 1,402 individuals, accounting for one-third of the total [1][4] - The total disclosed annual salary for 4,231 listed companies reached 5.789 billion yuan, with 13 chairpersons earning over 10 million yuan [1][4] - The number of chairpersons with annual salaries exceeding 10 million yuan has decreased from 27 in 2022 to 16 in 2023, and further down to 13 in 2024 [4] Salary Distribution - The top three highest-paid chairpersons are from the biopharmaceutical industry, with WuXi AppTec's chairman earning 41.8 million yuan, followed by Mindray Medical's chairman at 24.939 million yuan, and BeiGene's chairman at 20.1938 million yuan [2][3] - The salary distribution is characterized by an olive-shaped curve, with fewer individuals earning higher salaries; for instance, there are 381 individuals earning between 2 million and 3 million yuan, and only 67 earning between 4 million and 5 million yuan [6] Salary Changes - A total of 3,765 chairpersons had comparable salaries from 2023 to 2024, with 1,377 experiencing a decrease (37%) and 1,985 seeing an increase (58%) [8] - Notable salary reductions were observed among high-earning chairpersons, with some experiencing declines of over 90% due to poor company performance [9][10] Industry Performance - The salary trends reflect a dichotomy in industry performance, with high salaries in thriving sectors like media, electronics, and pharmaceuticals, while industries like real estate and finance are facing salary cuts [11][13] - The average salary for chairpersons in the media industry was 1.78 million yuan, the highest among 31 sectors, while the average salary in the construction and defense sectors was below 1 million yuan [12][13]